Uncategorized

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Published

on

Trodelvy’s latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead’s main business.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version